Literature DB >> 7991952

Chronic hypercapnia in obstructive sleep apnea-hypopnea syndrome.

S Javaheri1, G Colangelo, W Lacey, P S Gartside.   

Abstract

In order to determine the relationship between chronic hypercapnia and anthropomorphic data, pulmonary function tests and slopes of ventilatory responses to hypercapnia (HVCR) and hypoxia (HVR), we studied 55 patients with sleep apnea-hypopna syndrome (SAHS). Patients were divided into hypercapnic, PaCO2 > or = 45 mm Hg (Group I, n = 23, PaO2 = 61 +/- 10 and PaCO2 = 50 +/- 5 mm Hg, and [HCO3-] = 30 +/- 4 mEq/l [means +/- SD]) and normocapnic (or eucapnic), PaCO2 < 45 mm Hg (Group II, n = 32, PaO2 = 76 +/- 10 and PaCO2 = 39 +/- 4 mm Hg and [HCO3-] = 25 +/- 3 mEq/l [means +/- SD]) groups. When compared to the normocapnic group, hypercapnic patients were significantly heavier (with greater body surface area) and had significantly more severe restrictive and obstructive defects and impaired HVR and HCVR. The means (+/- SD) of some of the data follow (* indicates p < 0.05 when Group I is compared to Group II): [table: see text] When subgroups of hypercapnic and eucapnic patients with similar lung functions were compared, the subgroups differed significantly in their weights; conversely, in subgroups with comparable weights, lung function tests differed significantly. These data suggest that the mechanisms of chronic hypercapnia are multifactorial, and we hypothesize that, in the face of repetitive apneas and hypopneas, increased weight and abnormal lung function tests interact and contribute to the generation and maintenance of hypercapnia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7991952     DOI: 10.1093/sleep/17.5.416

Source DB:  PubMed          Journal:  Sleep        ISSN: 0161-8105            Impact factor:   5.849


  11 in total

1.  Obesity Hypoventilation Syndrome Epidemiology and Diagnosis.

Authors:  Jay S Balachandran; Juan Fernando Masa; Babak Mokhlesi
Journal:  Sleep Med Clin       Date:  2014-09

2.  Hypercapnia in overlap syndrome: possible determinant factors.

Authors:  Onofrio Resta; Maria Pia Foschino Barbaro; Caterina Brindicci; Maria Cristina Nocerino; Gennaro Caratozzolo; Monica Carbonara
Journal:  Sleep Breath       Date:  2002-03       Impact factor: 2.816

3.  Ventilatory responses to acute hypoxia and hypercapnia in humans with a patent foramen ovale.

Authors:  James T Davis; Lindsey M Boulet; Alyssa M Hardin; Alex J Chang; Andrew T Lovering; Glen E Foster
Journal:  J Appl Physiol (1985)       Date:  2018-12-06

4.  The prevalence and natural history of complex sleep apnea.

Authors:  Shahrokh Javaheri; Jason Smith; Eugene Chung
Journal:  J Clin Sleep Med       Date:  2009-06-15       Impact factor: 4.062

5.  Obesity hypoventilation syndrome.

Authors:  Laila Al Dabal; Ahmed S Bahammam
Journal:  Ann Thorac Med       Date:  2009-04       Impact factor: 2.219

6.  Adaptive pressure support servoventilation: a novel treatment for sleep apnea associated with use of opioids.

Authors:  Shahrokh Javaheri; Athar Malik; Jason Smith; Eugene Chung
Journal:  J Clin Sleep Med       Date:  2008-08-15       Impact factor: 4.062

7.  Impact of adherence with positive airway pressure therapy on hypercapnia in obstructive sleep apnea.

Authors:  Babak Mokhlesi; Aiman Tulaimat; Arthur T Evans; Yue Wang; Abed-Alrahman Itani; Hesham A Hassaballa; James J Herdegen; Edward J Stepanski
Journal:  J Clin Sleep Med       Date:  2006-01-15       Impact factor: 4.062

8.  Obesity Hypoventilation Syndrome and Anesthesia.

Authors:  Edmond H L Chau; Babak Mokhlesi; Frances Chung
Journal:  Sleep Med Clin       Date:  2012-12-14

Review 9.  Assessment and management of patients with obesity hypoventilation syndrome.

Authors:  Babak Mokhlesi; Meir H Kryger; Ronald R Grunstein
Journal:  Proc Am Thorac Soc       Date:  2008-02-15

10.  Obesity hypoventilation syndrome: prevalence and predictors in patients with obstructive sleep apnea.

Authors:  Babak Mokhlesi; Aiman Tulaimat; Ilja Faibussowitsch; Yue Wang; Arthur T Evans
Journal:  Sleep Breath       Date:  2007-06       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.